STEPS

New Drug Reviews

Glycopyrrolate (Lonhala Magnair) for Treatment of Chronic Obstructive Pulmonary Disease

 

Am Fam Physician. 2019 May 15;99(10):643-648.

Glycopyrrolate nebulizer solution (Lonhala Magnair) is labeled for long-term maintenance therapy of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It is available with a portable nebulizer for self-administration by patients.

 Enlarge     Print

DrugDosageDose formCost*

Glycopyrrolate (Lonhala Magnair)

One inhalation (25 mcg) twice daily

1-mL vial

$1,170


*—Estimated retail price of 30 days of treatment (60 vials) based on information obtained at https://www.goodrx.com (accessed February 7, 2019).

DrugDosageDose formCost*

Glycopyrrolate (Lonhala Magnair)

One inhalation (25 mcg) twice daily

1-mL vial

$1,170


*—Estimated retail price of 30 days of treatment (60 vials) based on information obtained at https://www.goodrx.com (accessed February 7, 2019).

Safety

Glycopyrrolate is an anticholinergic, which could theoretically induce narrow-angle glaucoma and worsen symptoms of urinary retention. Glycopyrrolate should not be used with other medications that have anticholinergic activity.1 It should not be initiated in patients during an acute exacerbation of COPD. All patients started on glycopyrrolate should have a short-acting beta agonist for treatment of acute symptoms and paradoxical bronchospasm. Glycopyrrolate should be avoided in patients with unstable cardiac disease because studies have not evaluated safety. Glycopyrrolate is excreted in breast milk and should not be used in pregnant and lactating women unless the expected benefit outweighs the potential risk. It is not approved for use in children.

Tolerability

Glycopyrrolate is well tolerated. In clinical trials, the pooled dropout rate due to adverse effects was 5%, compared with 9% for patients treated with placebo. Two 12-week randomized, placebo-controlled trials involved a total of 431 patients with moderate to severe COPD (average forced expiratory volume in one second [FEVI] of 52% of predicted). More than 2% of participants experienced adverse effects, including dyspnea (4.9% vs. 3% with placebo) and urinary tract infection (9% vs. 6% with placebo).1 No adjustment in dosage is necessary in older patients or in patients with hepatic impairment or mild to moderate renal disease.

Effectiveness

When added to treatment with a long-acting beta agonist, with or without an inhaled corticosteroid and ipratropium (Atrovent), glycopyrrolate will increase FEV1 by 81 to 96 mL, which is similar to the increase achieved with tiotropium (Spiriva).1,2 The effectiveness of glycopyrrolate was confirmed in a larger 48-week open-label study.3 Quality of life is significantly improved in one additional patient for every nine patients treated with glycopyrrolate vs. placebo, but glycopyrrolate has not been studied as the sole long-acting therapy for COPD.

Glycopyrrolate has not been evaluated in patients with mild COPD, and studies have not determined its effect on patient-oriented outcomes (e.g., risk of exacerbation, hospitalization).

Price

A one-month supply of glycopyrrolate (60 vials) costs approximately $1,170. This price includes the cost of the nebulizer for administration. In comparison, a one-month supply of tiotropium costs about $445.

Simplicity

The recommended dosage of glycopyrrolate is one 25-mcg inhalation twice daily. Patients should be instructed in the administration of glycopyrrolate as well as assembly and care of the nebulizer. Administration requires two to three minutes. No research has compared its ease of use with administration of a metered-dose inhaler.

Bottom Line

Glycopyrrolate is a safe alternative to long-acting muscarinic antagonists delivered by metered-dose inhaler for patients with moderate to severe COPD. However, it is significantly more expensive compared with other treatments. Its use should be limited to patients who cannot use a metered-dose inhaler.

Address correspondence to Montgomery Douglas, MD, at mdouglas@uchc.edu. Reprints are not available from the author.

Author disclosure: No relevant financial affiliations.

References

1. Daily Med. Drug label information. Lonhala Magnair–glycopyrrolate solution. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78166def-5e2f-42a6-a1f1-0253e5765632. Accessed January 7, 2019.

2. Kerwin E, Donohue JF, Goodin T, Tosiello R, Wheeler A, Ferguson GT. Efficacy and safety of glycopyrrolate/eFlow®CS (nebulized glycopyrrolate) in moderate-to-very-severe COPD: results from the Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer (GOLDEN) 3 and 4 randomized controlled trials. Respir Med. 2017;132:238–250.

3. Ferguson GT, Goodin T, Tosiello R, Wheeler A, Kerwin E. Long-term safety of glycopyrrolate/eFlow® CS in moderate-to-very-severe COPD: results from the Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer (GOLDEN) 5 randomized study. Respir Med. 2017;132:251–260.

STEPS new drug reviews cover Safety, Tolerability, Effectiveness, Price, and Simplicity. Each independent review is provided by authors who have no financial association with the drug manufacturer.

This series is coordinated by Allen F. Shaughnessy, PharmD, MMedEd, Assistant Medical Editor.

A collection of STEPS published in AFP is available at https://www.aafp.org/afp/steps.

 

 

Copyright © 2019 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


More in AFP

More in Pubmed

MOST RECENT ISSUE


Nov 15, 2020

Access the latest issue of American Family Physician

Read the Issue


Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article